MedTrace Logo

Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR

NCT00143039 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2014-12-19

No results posted yet for this study

Summary

The objective of this pilot study is to prospectively evaluate amniotic fluid of pregnancies complicated by non-immune hydrops and severe symmetrical intrauterine growth restriction by tandem mass spectrometry for inborn errors of metabolism.

Conditions

  • Hydrops Fetalis
  • Fetal Growth Retardation

Interventions

PROCEDURE

Tandem MS test for inborn errors of metabolism

Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.

Sponsors & Collaborators

  • Obstetrix Medical Group

    lead INDUSTRY

Principal Investigators

  • Karrie Francois, MD · Pediatrix-Obstetrix Medical Group, Inc.

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143039 on ClinicalTrials.gov